Pharmacokinetics, safety and preliminary efficacy of conbercept eye drops for corneal neovascularization: Results from phase I/IIa studies
British Journal of Clinical Pharmacology · 17.08.2026
DOI: 10.1002/bcp.70707 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 17.08.2026. Verfasst von Qi Shen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Chengdu Kanghong Biotechnology Co. Ltd.
Abstract (Originalsprache)
Aims
Vascular endothelial growth factor (VEGF) drives corneal neovascularization (CorNV), yet no anti‐VEGF eye drops are clinically available. We report phase I/IIa trials of KH906, a novel topical anti‐VEGF agent.
Methods
Trial 1 was a phase I, open‐label, dose‐escalation study in healthy adults receiving KH906 at 0.1, 0.5, or 1.0 mg/mL. Trial 2 was a phase I, multicentre, open‐label, dose‐escalation study in patients with CorNV at the same doses. Trial 3 was a phase IIa, randomized, double‐masked, placebo‐controlled study assigning patients 1:1:1 to 0.5 mg/mL KH906, 1.0 mg/mL KH906, or placebo. Primary endpoints were safety, tolerability and pharmacokinetics (Trials 1 and 2) and safety, tolerability and efficacy (Trial 3).
Results
From 10 December 2018 to 16 June 2021, 18 healthy participants and 39 patients with CorNV were enrolled. One treatment‐related adverse event occurred: a mild corneal epithelial defect in the 1.0‐mg/mL group in Trial 3. No serious or other drug‐related adverse events were observed. In Trial 2, KH906 reduced the CorNV area and vessel length. In Trial 3, at Day 28, mean changes in CorNV area were −1.2 (0.8), −1.6 (1.1) and −0.7 (1.1), and mean changes in CorNV length were −8.0 (7.3), −6.6 (5.9) and −1.7 (7.9), in the 0.5‐mg/mL KH906, 1.0‐mg/mL KH906 and placebo groups, respectively. The 1.0‐mg/mL dose produced greater reduction of the CorNV area than lower doses, indicating a dose–response effect.
Conclusions
KH906 appears safe and well tolerated and demonstrates preliminary efficacy in reducing CorNV, with higher doses showing greater effect, supporting further clinical development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China.
- Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, China.
- Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Pharmacy, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital, Sichuan University, Sichuan University, Chengdu, China.
- Corneal & External Diseases, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
- Ophthalmology and Corneology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Zhu Luo
Förderung
- Chengdu Kanghong Biotechnology Co. Ltd
Zitieren
APA
Shen, Q., Shu, P., Wang, Z., Yuan, J., Pan, Z., Pei, C., Hong, J., Yang, Y., Zhang, M., Ke, X., Wang, X., Luo, Z., Ma, K., & Deng, Y. (2026). Pharmacokinetics, safety and preliminary efficacy of conbercept eye drops for corneal neovascularization: Results from phase I/IIa studies. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70707
Vancouver
Shen Q, Shu P, Wang Z, Yuan J, Pan Z, Pei C, et al. Pharmacokinetics, safety and preliminary efficacy of conbercept eye drops for corneal neovascularization: Results from phase I/IIa studies. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70707
BibTeX
@article{Shen2026,
author = {Shen, Qi and Shu, Pei and Wang, Zhenlei and Yuan, Jin and Pan, Zhiqiang and Pei, Cheng and Hong, Jing and Yang, Yanning and Zhang, Mingchang and Ke, Xiao and Wang, Xinguo and Luo, Zhu and Ma, Ke and Deng, Yingping},
title = {Pharmacokinetics, safety and preliminary efficacy of conbercept eye drops for corneal neovascularization: Results from phase I/IIa studies},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70707}
}
EUVIMED